Data Book
2024年3月期
Fiscal year ended March 31, 2024
株式会社スズケン
Suzuken Company Limited
2024年5月
May 2024
この資料に関するお問い合わせは山本、長縄まで(Tel: 052-950-6302)
If you have any inquiry about the Data Book,
please contact:Messrs. Yamamoto or Naganawa.
Tel: +81-52-950-6302
目 次
Contents
ページ | ||
1. 企業集団の状況(2024年3月31日現在) The Suzuken Group (as of March 31, 2024) | ||
(1)企業集団の状況 The Suzuken Group | 2 | |
(2)主な事業再編 Major additions to the Suzuken Group | 3 | |
2. 連結決算概況 Consolidated Financial Overview | ||
(1)経営成績 Business performance | 4 | |
①金額 Results ②売上比 Ratio to sales ③増加率 Year-on-year change | ||
(2)財政状態 Financial Position | 5 | |
(3)キャッシュ・フローの状況 Cash Flows | ||
(4)売上債権、棚卸資産、仕入債務の状況 Trade receivables,inventories and trade payables | ||
(5)設備投資額、減価償却費 Capital expenditures, depreciation and amortization | 6 | |
(6)販売費及び一般管理費 Selling, general and administrative expenses | ||
(7)人員配置 Deployment of personnel | ||
3. セグメント状況 Segment Information | ||
(1)売上高 Net sales | 7 | |
(2)営業利益・売上比 Operating income, ratio to net sales | ||
(3)医薬品卸売事業 Pharmaceutical distribution business | 8 | |
①-1 | 地域別売上高 Net sales by region | |
①-2 | 地域別営業拠点数 Number of sales offices by region | |
※参考 医療用医薬品 地域別シェア(薬価ベース) | ||
Pharmaceuticals: Share by region (Price basis) | ||
②-1 | 医療用医薬品 メーカー別売上高(上位10社) | 9 |
Pharmaceuticals: Net sales by top ten manufacturers | ||
②-2 | 医療用医薬品 メーカー別売上高構成比(上位10社) | |
Pharmaceuticals: Percentage of total net sales by top ten manufacturers | ||
③-1 | 医療用医薬品 販売先別売上高 | 10 |
Pharmaceuticals: Net sales by client type | ||
③-2 | 医療用医薬品 販売先別売上高構成比 | |
Pharmaceuticals: Net sales composition by client type | ||
4. 株式の状況(2024年3月31日現在) Stock Information (as of March 31, 2024) | ||
(1)所有者別分布状況 Shareholder composition | 11 | |
(2)大株主の状況 Major shareholders | 12 | |
(3)配当状況 Dividends | ||
5. 連結財務諸表 Consolidated Financial Statements | ||
(1)連結貸借対照表 Consolidated balance sheets | 13 | |
(2)連結損益計算書 Consolidated statements of income | 15 | |
(3)連結株主資本等変動計算書 Consolidated statements of changes in net assets | 16 | |
6. セグメント別損益表 Statements of Income by Segment | ||
(1)医薬品卸売事業 Pharmaceutical distribution business | 18 | |
(2)ヘルスケア製品開発事業 Healthcare Product Development business | ||
(3)地域医療介護支援事業 Community Healthcare and Nursing Care Support business | 19 | |
(4)医療関連サービス等事業 Healthcare-related service business | ||
7. 単体財務諸表 Nonconsolidated Financial Statements | ||
(1)単体貸借対照表 Nonconsolidated balance sheets | 20 | |
(2)単体損益計算書 Nonconsolidated statements of income | 22 |
- 1 -
1.企業集団の状況(2024年3月31日現在) The Suzuken Group (as of March 31, 2024)
(1)企業集団の状況 The Suzuken Group
2024年3月期 連結子会社数 45 社 (2023年3月期 50社)
Number of consolidated subsidiaries as of March 31, 2024: 45 (As of March 31, 2023:50 )
事業区分 | 事業内容 | 主な子会社名 |
Business segment | Business activities | Major subsidiaries |
株式会社 スズケン | ||
Suzuken Co., Ltd. | ||
株式会社 スズケン岩手 | ||
Suzuken Iwate Co., Ltd. | ||
ナカノ薬品 株式会社 | ||
Nakano Yakuhin Co., Ltd. | ||
株式会社 サンキ | ||
Sanki Corporation | ||
医薬品卸売事業 | 医薬品・医療機器などの販売 | |
株式会社 アスティス | ||
Pharmaceutical | ||
Distribution | Sales of pharmaceuticals and medical equipment | ASTIS Co., Ltd. |
株式会社 翔薬 | ||
Shoyaku Co., Ltd. | ||
株式会社 スズケン沖縄薬品 | ||
Suzuken Okinawa Yakuhin Co., Ltd. | ||
医薬品を中心に取り扱う物流専門会社 | ||
(主に医薬品卸から医療機関・調剤薬局への輸配送) | 株式会社 エス・ディ・ロジ | |
Logistics specialists mainly handling pharmaceuticals | S.D.Logi CO., LTD. | |
(Distribution from wholesalers to hospitals and pharmacies) | ||
医薬品・診断用試薬などの研究開発と製造販売 | 株式会社 三和化学研究所 | |
ヘルスケア製品 | R&D, manufacture and sales of pharmaceuticals and | Sanwa Kagaku Kenkyusho Co., Ltd. |
開発事業 | diagnostic reagents | |
Healthcare Product | ||
Development | 医療機器の製造販売 | ケンツメディコ 株式会社 |
Manufacture and sales of medical equipment | Kenzmedico Co., Ltd. | |
調剤薬局の経営 | 株式会社 ユニスマイル | |
地域医療介護 | Operation of dispensing pharmacies | Unismile Co., Ltd. |
支援事業 | ||
Community | サンキ・ウエルビィ 株式会社 | |
Healthcare and | ||
Sanki Wellbe Co., Ltd. | ||
Nursing Care | 在宅介護および施設介護 | |
Support | Home nursing care and facility nursing care | 株式会社 エスケアメイト |
S-Care Mate Co., Ltd. | ||
希少疾病用医薬品の流通に関する総合支援 | ||
(販売、流通管理、情報提供等) | 株式会社 エス・ディ・コラボ | |
医療関連 | Total support for orphan drug distribution | S.D.COLLABO CO.,Ltd. |
(Marketing,Distribution management,Providing information) | ||
サービス等事業 | ||
Healthcare-related | 医薬品を中心に取り扱う物流専門会社 | |
Services | ||
(主に医薬品メーカーから医薬品卸への輸配送) | 中央運輸 株式会社 | |
Logistics specialists mainly handling pharmaceuticals | Chuounyu Co., Ltd. | |
(Distribution from manufacturers to wholesalers) | ||
- 2 -
1.企業集団の状況(2024年3月31日現在) The Suzuken Group (as of March 31, 2024)
(2)主な事業再編
1994年 加藤薬品㈱、神弘薬品㈱と合併
1996年 ㈱熊谷薬品(現社名 ㈱スズケン岩手)を子会社化 ㈱ドーエーメディックスと合併
1998年 ㈱秋山愛生舘と合併
1999年 ナカノ薬品㈱を子会社化
2002年 オオモリ薬品㈱と合併
2003年 ㈱安藤薬業公司と合併 ㈱サンキを子会社化
2005年 沖縄薬品㈱を子会社化 ㈱アスティスを子会社化
㈱スズケン沖縄が沖縄薬品㈱と合併して、㈱スズケン沖縄薬品に社名変更
2006年 ㈱翔薬を子会社化
全国展開を達成
(2)Major additions to the Suzuken Group
1994 Merged with Kato Yakuhin Co., Ltd. and Shinko Yakuhin Co., Ltd.
1996 Acquired Kumagai Yakuhin Co., Ltd. (now Suzuken Iwate Co., Ltd.) Merged with Doei Medics Co., Ltd.
1998 Merged with Akiyama Inc.
1999 Acquired Nakano Yakuhin Co., Ltd.
2002 Merged with Ohmori Co., Ltd.
2003 Merged with Ando Chemical Works Co., Ltd. Acquired Sanki Corporation
2005 Acquired Okinawa Yakuhin Co., Ltd.
Acquired ASTIS Co., Ltd.
Suzuken Okinawa and Okinawa Yakuhin merged to form Suzuken Okinawa Yakuhin Co., Ltd.
2006 Acquired Shoyaku Co., Ltd.
Suzuken develops business nationwide
- 3 -
2.連結決算概況 Consolidated Financial Overview
(1)経営成績 Business performance | |
①金額 Results | 単位:百万円 (Millions of yen) |
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 |
売上高 Net sales | 2,213,478 | 2,128,218 | 2,239,112 | 2,314,828 |
差引売上総利益 Balance of gross profit (loss) | 194,124 | 157,840 | 167,332 | 179,694 |
販売費及び一般管理費 | 161,552 | 148,683 | 147,216 | 147,089 |
Selling, general and administrative expenses | ||||
営業利益 Operating income | 32,571 | 9,156 | 20,116 | 32,605 |
経常利益 Ordinary income | 41,467 | 18,272 | 23,418 | 36,376 |
親会社株主に帰属する当期純利益 | 28,213 | 7,895 | 14,393 | 20,345 |
Net income attributable to owners of the parent | ||||
1株当たり当期純利益(円) | 310.26 | 88.52 | 163.19 | 236.47 |
Basic net income per share(Yen) | ||||
自己資本当期純利益率(%) | 6.9 | 1.9 | 3.4 | 4.9 |
Return on equity | ||||
総資産経常利益率(%) | 3.6 | 1.6 | 2.1 | 3.2 |
Return on assets | ||||
24/3
March 2024
2,386,493
185,249
150,373
34,875
38,351
29,016
357.88
7.0
3.2
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
②売上比 Ratio to sales
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 |
差引売上総利益 Balance of gross profit (loss) | 8.77 | 7.42 | 7.47 | 7.76 |
販売費及び一般管理費 | 7.30 | 6.99 | 6.57 | 6.35 |
Selling, general and administrative expenses | ||||
営業利益 Operating income | 1.47 | 0.43 | 0.90 | 1.41 |
経常利益 Ordinary income | 1.87 | 0.86 | 1.05 | 1.57 |
親会社株主に帰属する当期純利益 | 1.27 | 0.37 | 0.64 | 0.88 |
Net income attributable to owners of the parent | ||||
単位:%
24/3
March 2024
7.76
6.30
1.46
1.61
1.22
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
③増加率 Year-on-year change | 単位:% | ||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 |
売上高 Net sales | 3.8 | △ 3.9 | - | 3.4 | 3.1 |
差引売上総利益 Balance of gross profit (loss) | 2.6 | △ 18.7 | - | 7.4 | 3.1 |
販売費及び一般管理費 | △ 0.3 | △ 8.0 | △ 1.0 | △ 0.1 | 2.2 |
Selling, general and administrative expenses | |||||
営業利益 Operating income | 19.6 | △ 71.9 | - | 62.1 | 7.0 |
経常利益 Ordinary income | 14.7 | △ 55.9 | 28.2 | 55.3 | 5.4 |
親会社株主に帰属する当期純利益 | △ 6.6 | △ 72.0 | 82.3 | 41.4 | 42.6 |
Net income attributable to owners of the parent | |||||
※22/3の増減率につきましては、表示方法の変更に伴い記載しておりません。
※The percentage changes from the fiscal year 2021 are not listed due to the changes in the indication method.
- 4 -
2.連結決算概況 Consolidated Financial Overview
(2)財政状態 Financial Position | 単位:百万円 (Millions of yen) | |||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 | March 2023 | |
資本金 Common stock | 13,546 | 13,546 | 13,546 | 13,546 | 13,546 | |
純資産 Equity | 412,708 | 417,912 | 418,062 | 411,525 | 416,428 | |
総資産 Total assets | 1,112,507 | 1,114,421 | 1,141,717 | 1,146,097 | 1,228,686 | |
自己資本比率(%) Equity ratio | 37.0 | 37.4 | 36.6 | 35.9 | 33.9 | |
1株当たり純資産(円) | 4,618.33 | 4,675.23 | 4,749.59 | 4,970.38 | 5,361.96 | |
Basic net income per share(Yen) | ||||||
(3)キャッシュ・フローの状況 Cash Flows | 単位:百万円 (Millions of yen) | |||||
算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 | |
営業活動による | △ 25,817 | 15,602 | 9,520 | 37,270 | 87,216 | |
Net cash (used in) provided by Operating activities | ||||||
税金等調整前当期純利益 | 41,808 | 12,557 | 22,484 | 30,594 | 42,793 | |
Income before income taxes | ||||||
減価償却費 | 10,719 | 10,179 | 9,560 | 8,639 | 8,563 | |
Depreciation and amortization | ||||||
売上債権の増減額 | 13,897 | △ 3,578 | △ 25,046 | △ 2,620 | △ 19,028 | |
Decrease (increase) in trade notes and accounts receivable | ||||||
棚卸資産の増減額 | 6,385 | 7,107 | △ 5,177 | △ 1,582 | △ 3,086 | |
Decrease (increase) in inventories | ||||||
仕入債務の増減額 | △ 86,371 | △ 392 | 20,023 | 2,234 | 78,057 | |
(Decrease) increase in trade notes and accounts payables | ||||||
投資活動による | 1,199 | △ 14,586 | 1,439 | △ 46,361 | 10,350 | |
Net cash provided by investing activities | ||||||
財務活動による | △ 17,167 | △ 7,393 | △ 11,599 | △ 26,219 | △ 31,716 | |
Net cash used in financing activities | ||||||
現金及び現金同等物期末残高 | 175,215 | 168,818 | 168,215 | 132,872 | 198,745 | |
Cash and cash equivalents, end of year | ||||||
1株当たり営業キャッシュ・フロー(円) | △ 290 | 175 | 108 | 450 | 1,123 | |
Operating cash flow per share (Yen) | ||||||
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items. The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
<ご参考>銀行休日に伴う買掛金未決済による影響を除いたキャッシュフロー
Reference: Cash flows excluding the impact of unsettled accounts payable due to the term-end falling on a bank holiday
営業活動による | 49,145 | 15,602 | 9,520 | 37,270 | 8,189 | |
Net cash (used in) provided by Operating activities | ||||||
現金及び現金同等物期末残高 | 175,215 | 168,818 | 168,215 | 132,872 | 119,717 | |
Cash and cash equivalents, end of year | ||||||
(4)売上債権、棚卸資産、仕入債務の状況 | ||||||
Trade receivables, inventories and trade payables | 単位:百万円、ヶ月 (Millions of yen, months) | |||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 | |
月平均売上高 Average net sales per month | 184,456 | 177,351 | 186,592 | 192,902 | 198,874 | |
売上債権 Trade receivables (months) | 486,991 | 490,569 | 518,408 | 521,028 | 539,740 | |
売上債権回転期間(ヶ月) | 2.64 | 2.77 | 2.78 | 2.70 | 2.71 | |
Trade receivables turnover period (months) | ||||||
棚卸資産 Inventories | 139,727 | 132,619 | 137,989 | 139,369 | 142,356 | |
棚卸資産回転期間(ヶ月) | 0.76 | 0.75 | 0.74 | 0.72 | 0.72 | |
Inventory turnover period (months) | ||||||
仕入債務 Trade payables | 644,161 | 643,769 | 664,280 | 666,515 | 744,183 | |
仕入債務回転期間(ヶ月) | 3.49 | 3.63 | 3.56 | 3.46 | 3.74 | |
Trade payables turnover period (months) | ||||||
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items. The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
<ご参考>銀行休日に伴う買掛金未決済による影響を除いた仕入債務
Reference: Trade payables exclude the impact of accounts that remain outstanding due to a bank holiday
仕入債務 Trade payables | 644,161 | 643,769 | 664,280 | 666,515 | 665,155 |
仕入債務回転期間(ヶ月) | 3.49 | 3.63 | 3.56 | 3.46 | 3.34 |
Trade payables turnover period (months) | |||||
- 5 -
2.連結決算概況 Consolidated Financial Overview
(5)設備投資額、減価償却費 | |
Capital expenditures, depreciation and amortization | 単位:百万円 (Millions of yen) |
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 |
設備投資額 Capital expenditures | 9,552 | 8,184 | 14,907 | 17,748 |
うち情報投資 Including IT investment | 2,314 | 2,334 | 3,280 | 2,847 |
減価償却費 Depreciation and amortization | 10,719 | 10,179 | 9,560 | 8,639 |
24/3
March 2024
16,063
4,993
8,563
(6)販売費及び一般管理費 | |
Selling, general and administrative expenses | 単位:百万円、% (Millions of yen/%) |
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 |
売上高 Net sales | 2,213,478 | 2,128,218 | 2,239,112 | 2,314,828 |
販売費及び一般管理費 | 161,552 | 148,683 | 147,216 | 147,089 |
Selling, general and administrative expenses | ||||
売上比 Ratio to net sales (%) | 7.30 | 6.99 | 6.57 | 6.35 |
人件費 Personnel costs | 91,991 | 84,697 | 80,899 | 79,440 |
売上比 Ratio to net sales (%) | 4.16 | 3.98 | 3.61 | 3.43 |
研究開発費 | 4,648 | 3,453 | 4,592 | 2,952 |
Research and development costs | ||||
売上比 Ratio to net sales (%) | 0.21 | 0.16 | 0.21 | 0.13 |
のれん償却額 Amortization of goodwill | 707 | 129 | 459 | 205 |
売上比 Ratio to net sales (%) | 0.03 | 0.01 | 0.02 | 0.01 |
減価償却費 Depreciation and amortization | 8,362 | 7,812 | 7,074 | 6,310 |
売上比 Ratio to net sales (%) | 0.38 | 0.37 | 0.32 | 0.27 |
上記以外 Others | 55,842 | 52,589 | 54,190 | 58,180 |
売上比 Ratio to net sales (%) | 2.52 | 2.47 | 2.42 | 2.51 |
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
24/3
March 2024
2,386,493
150,373
6.30
79,759
3.34
3,279
0.14
181
0.01
6,195
0.26
60,922
2.55
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
(7)人員配置 ※期末従業員数 | ||||||||
Deployment of personnel: Number of employees at fiscal year-ends | 単位:人 | (Number of employees) | ||||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |||
科目 Item | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 | |||
医薬品卸売事業 | 9,807 | 9,574 | 8,563 | 8,143 | 7,987 | |||
Pharmaceutical distribution business | ||||||||
ヘルスケア製品開発事業 | - | - | - | 887 | 878 | |||
Healthcare Product Development business | ||||||||
地域医療介護支援事業 | - | - | - | 3,765 | 3,574 | |||
Community Healthcare and Nursing Care Support business | ||||||||
医療関連サービス等事業 | - | - | - | 634 | 647 | |||
Healthcare-related service business | ||||||||
合計 Total | 15,477 | 15,041 | 14,032 | 13,429 | 13,086 | |||
※24/3にセグメントの変更を行っております。ヘルスケア製品開発事業、地域医療介護支援事業、医療関連サービス等事業の23/3につきましては、 セグメント変更後の数値に組み替えております。
※We have made changes to our business segments beginning with the fiscal year 2023. Consequently, we have restated the figures for the fiscal year 2022 in our Healthcare Product Development, Community Healthcare and Nursing Care Support, and Healthcare-related Services segments to reflect these changes.
- 6 -
3.セグメント状況 Segment Information
(1)売上高 Net sales | 単位:百万円 (Millions of yen) | |||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |
セグメント Segment | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 | |
医薬品卸売事業 | 2,125,373 | 2,039,954 | 2,150,673 | 2,226,918 | 2,299,180 | |
Pharmaceutical distribution business | ||||||
医療用医薬品 | 1,928,625 | 1,842,709 | 1,924,078 | 1,977,974 | 2,059,947 | |
Pharmaceuticals | ||||||
診断薬 | 87,111 | 87,497 | 103,810 | 121,503 | 110,191 | |
Diagnostic reagents | ||||||
医療機器・材料 | 69,736 | 68,095 | 70,119 | 73,096 | 74,519 | |
Medical equipment and supplies | ||||||
その他 | 39,900 | 41,651 | 52,664 | 54,344 | 54,522 | |
Other | ||||||
ヘルスケア製品開発事業 | - | - | - | 47,440 | 51,296 | |
Healthcare Product Development business | ||||||
地域医療介護支援事業 | - | - | - | 97,979 | 97,463 | |
Community Healthcare and Nursing Care Support business | ||||||
医療関連サービス等事業 | - | - | - | 215,417 | 261,604 | |
Healthcare-related service business | ||||||
セグメント間消去 | - | - | - | △ 272,927 | △ 323,051 | |
Eliminations of intercompany transactions | ||||||
合計 | 2,213,478 | 2,128,218 | 2,239,112 | 2,314,828 | 2,386,493 | |
Total | ||||||
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
※24/3にセグメントの変更を行っております。ヘルスケア製品開発事業、地域医療介護支援事業、医療関連サービス等事業の23/3につきましては、 セグメント変更後の数値に組み替えております。
※We have made changes to our business segments beginning with the fiscal year 2023. Consequently, we have restated the figures for the fiscal year 2022 in our Healthcare Product Development, Community Healthcare and Nursing Care Support, and Healthcare-related Services segments to reflect these changes.
(2)営業利益・売上比 Operating income,ratio to nat sales | 単位:百万円、% (Millions of yen/%) | |||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 | |
セグメント Segment | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 | |
医薬品卸売事業 | 金額 Amount | 28,084 | 4,093 | 14,733 | 27,050 | 30,424 |
Pharmaceutical distribution business | 売上比 Ratio to net sales (%) Total | 1.32 | 0.20 | 0.69 | 1.21 | 1.32 |
ヘルスケア製品開発事業 | 金額 Amount | - | - | - | 1,560 | 1,597 |
Healthcare Product Development | ||||||
売上比 Ratio to net sales (%) Total | - | - | - | 3.29 | 3.11 | |
business | ||||||
地域医療介護支援事業 | 金額 Amount | - | - | - | 2,592 | 1,690 |
Community Healthcare and Nursing Care | ||||||
売上比 Ratio to net sales (%) Total | - | - | - | 2.65 | 1.73 | |
Support business | ||||||
医療関連サービス等事業 | 金額 Amount | - | - | - | 1,124 | 1,107 |
Healthcare-related service business | 売上比 Ratio to net sales (%) Total | - | - | - | 0.52 | 0.42 |
セグメント間消去 | 金額 Amount | - | - | - | 277 | 56 |
Eliminations of intercompany | ||||||
transactions | ||||||
合計 | 金額 Amount | 32,571 | 9,156 | 20,116 | 32,605 | 34,875 |
Total | 売上比 Ratio to net sales (%) Total | 1.47 | 0.43 | 0.90 | 1.41 | 1.46 |
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
※24/3にセグメントの変更を行っております。ヘルスケア製品開発事業、地域医療介護支援事業、医療関連サービス等事業の23/3につきましては、 セグメント変更後の数値に組み替えております。
※We have made changes to our business segments beginning with the fiscal year 2023. Consequently, we have restated the figures for the fiscal year 2022 in our Healthcare Product Development, Community Healthcare and Nursing Care Support, and Healthcare-related Services segments to reflect these changes.
- 7 -
3.セグメント状況 Segment Information
(3)医薬品卸売事業 Pharmaceutical distribution business
①-1 | 地域別売上高 Net sales by region | 単位:百万円 (Millions of yen) |
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
地域 Region | March 2020 | March 2021 | March 2022 | March 2023 |
北海道 Hokkaido | 118,287 | 111,370 | 109,136 | 114,859 |
東北 Tohoku | 93,113 | 87,671 | 92,749 | 92,429 |
関東 Kanto | 747,637 | 716,079 | 767,013 | 800,641 |
甲信越 Koshinetsu | 68,710 | 64,268 | 71,149 | 72,312 |
東海 Tokai | 341,220 | 326,369 | 346,466 | 362,288 |
北陸 Hokuriku | 54,052 | 52,135 | 54,017 | 55,480 |
近畿 Kinki | 310,611 | 302,750 | 317,340 | 335,088 |
中国 Chugoku | 109,143 | 104,614 | 109,308 | 108,003 |
四国 Shikoku | 86,683 | 83,999 | 87,286 | 91,795 |
九州/沖縄 Kyushu/Okinawa | 195,602 | 190,366 | 195,921 | 193,921 |
輸出 Exports | 311 | 329 | 283 | 97 |
全国計 Nationwide total | 2,125,373 | 2,039,954 | 2,150,673 | 2,226,918 |
24/3
March 2024
111,010
96,766
830,594
73,830
372,630
56,785
348,625
109,802
93,392
205,742
2,299,180
※23/3より受入情報収入等の表示方法の変更を行っております。22/3につきましては、受入情報収入等の表示方法の 変更を反映した遡及適用後の数値を記載しております。
※Beginning from the fiscal year 2022, changes were made to the indication method for "Commission for supplying sales data" and other items.
The figures for the fiscal year 2021 are retroactively adjusted to reflect the indication method change in "Commission for supplying sales data" and other items.
①-2 地域別営業拠点数 Number of sales offices by region
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 |
地域 Region | March 2020 | March 2021 | March 2022 | March 2023 |
北海道 Hokkaido | 16 | 16 | 16 | 16 |
東北 Tohoku | 20 | 20 | 20 | 20 |
関東 Kanto | 51 | 51 | 50 | 49 |
甲信越 Koshinetsu | 8 | 8 | 8 | 8 |
東海 Tokai | 24 | 24 | 22 | 22 |
北陸 Hokuriku | 7 | 7 | 7 | 7 |
近畿 Kinki | 27 | 27 | 25 | 25 |
中国 Chugoku | 18 | 18 | 18 | 16 |
四国 Shikoku | 11 | 11 | 11 | 11 |
九州/沖縄 Kyushu/Okinawa | 42 | 40 | 39 | 35 |
全国計 Nationwide total | 224 | 222 | 216 | 209 |
24/3
March 2024
16
20
49
8
22
6
25
16
11
33
206
<参考> 医療用医薬品 地域別シェア(薬価ベース) Pharmaceuticals: Share by region (Price basis)
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | |
地域 Region | March 2020 | March 2021 | March 2022 | March 2023 | |
北海道 Hokkaido | 23.69 | 23.23 | 22.17 | 22.46 | |
東北 Tohoku | 13.75 | 13.62 | 14.22 | 13.78 | |
関東 Kanto | 23.78 | 23.74 | 24.40 | 24.35 | |
甲信越 Koshinetsu | 18.45 | 18.14 | 19.81 | 19.47 | |
東海 Tokai | 29.74 | 29.35 | 29.31 | 29.89 | |
北陸 Hokuriku | 23.31 | 22.96 | 23.15 | 22.96 | |
近畿 Kinki | 19.73 | 20.00 | 20.29 | 20.85 | |
中国 Chugoku | 18.16 | 18.07 | 18.52 | 17.88 | |
四国 Shikoku | 26.49 | 26.58 | 27.12 | 28.01 | |
九州/沖縄 Kyushu/Okinawa | 18.24 | 18.56 | 18.44 | 17.71 | |
全国計 Nationwide total | 21.93 | 21.90 | 22.26 | 22.29 |
単位:%
24/3
March 2024
21.13
14.04
23.94
19.16
29.25
22.39
20.67
17.48
27.81
17.90
21.99
- 8 -
3.セグメント状況 Segment Information
(3)医薬品卸売事業 Pharmaceutical distribution business
②-1 医療用医薬品 メーカー別売上高(上位10社) | |||||
Pharmaceuticals: Net sales by top ten manufacturers | 単位:百万円 (Millions of yen) | ||||
決算期 Fiscal year ended | 20/3 | 21/3 | 22/3 | 23/3 | 24/3 |
メーカー Manufacturer | March 2020 | March 2021 | March 2022 | March 2023 | March 2024 |
MSD㈱ MSD K.K. | 78,841 | 69,416 | 61,004 | 77,582 | 103,879 |
第一三共㈱ DAIICHI SANKYO COMPANY, LIMITED | 104,058 | 92,651 | 89,849 | 84,671 | 93,790 |
アストラゼネカ㈱ AstraZeneca K.K. | 54,305 | 55,002 | 70,002 | 77,451 | 88,766 |
小野薬品工業㈱ Ono Pharmaceutical Co.,Ltd. | 50,102 | 50,493 | 53,175 | 62,734 | 69,911 |
アステラス製薬㈱ Astellas Pharma Inc. | 100,858 | 79,521 | 74,709 | 67,143 | 68,650 |
ギリアド・サイエンシズ㈱ Gilead Sciences , Inc | 18,942 | 23,421 | 32,184 | 68,361 | 63,870 |
田辺三菱製薬㈱ Mitsubishi Tanabe Pharma Corporation | 66,999 | 65,079 | 63,733 | 62,319 | 60,280 |
大塚製薬㈱ Otsuka Pharmaceutical Co., Ltd. | 77,211 | 67,381 | 63,975 | 60,987 | 58,545 |
中外製薬㈱ Chugai Pharmaceutical Co., Ltd. | 69,114 | 63,121 | 66,894 | 64,434 | 57,849 |
ファイザー㈱ Pfizer Japan Inc. | 96,277 | 89,060 | 71,173 | 49,869 | 53,547 |
その他 Others | 1,211,913 | 1,187,560 | 1,277,375 | 1,302,416 | 1,340,854 |
合計 Total | 1,928,625 | 1,842,709 | 1,924,078 | 1,977,974 | 2,059,947 |
②-2 医療用医薬品 メーカー別売上高構成比(上位10社)
Pharmaceuticals: Percentage of total net sales by top ten manufacturers
決算期 Fiscal year ended | ||||
メーカー Manufacturer | ||||
MSD㈱ MSD K.K. | 4.1 | 3.8 | 3.2 | 3.9 |
第一三共㈱ DAIICHI SANKYO COMPANY, LIMITED | 5.4 | 5.0 | 4.7 | 4.3 |
アストラゼネカ㈱ AstraZeneca K.K. | 2.8 | 3.0 | 3.6 | 3.9 |
小野薬品工業㈱ Ono Pharmaceutical Co.,Ltd. | 2.6 | 2.7 | 2.8 | 3.2 |
アステラス製薬㈱ Astellas Pharma Inc. | 5.2 | 4.3 | 3.9 | 3.4 |
ギリアド・サイエンシズ㈱ Gilead Sciences , Inc | 1.0 | 1.3 | 1.7 | 3.5 |
田辺三菱製薬㈱ Mitsubishi Tanabe Pharma Corporation | 3.5 | 3.5 | 3.3 | 3.2 |
大塚製薬㈱ Otsuka Pharmaceutical Co., Ltd. | 4.0 | 3.7 | 3.3 | 3.1 |
中外製薬㈱ Chugai Pharmaceutical Co., Ltd. | 3.6 | 3.4 | 3.5 | 3.3 |
ファイザー㈱ Pfizer Japan Inc. | 5.0 | 4.8 | 3.7 | 2.5 |
その他 Others | 62.8 | 64.4 | 66.4 | 65.8 |
合計 Total | 100.0 | 100.0 | 100.0 | 100.0 |
単位:%
5.0
4.6
4.3
3.4
3.3
3.1
2.9
2.8
2.8
2.6
65.1
100.0
- 9 -
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Suzuken Co. Ltd. published this content on 15 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 11:06:47 UTC.